Efficacy, tolerability, and safety of infliximab biosimilar in comparison to originator biologic and adalimumab in patients with Crohn disease.

MLA

Kaniewska, Magdalena, et al. “Efficacy, Tolerability, and Safety of Infliximab Biosimilar in Comparison to Originator Biologic and Adalimumab in Patients with Crohn Disease.” Polish Archives of Internal Medicine, vol. 129, no. 7/8, July 2019, pp. 484–89. EBSCOhost, https://doi.org/10.20452/pamw.14901.

APA

Kaniewska, M., Rosołowski, M., & Rydzewska, G. (2019). Efficacy, tolerability, and safety of infliximab biosimilar in comparison to originator biologic and adalimumab in patients with Crohn disease. Polish Archives of Internal Medicine, 129(7/8), 484–489. https://doi.org/10.20452/pamw.14901

Chicago

Kaniewska, Magdalena, Mariusz Rosołowski, and Grażyna Rydzewska. 2019. “Efficacy, Tolerability, and Safety of Infliximab Biosimilar in Comparison to Originator Biologic and Adalimumab in Patients with Crohn Disease.” Polish Archives of Internal Medicine 129 (7/8): 484–89. doi:10.20452/pamw.14901.